Some people fight fire with fire. I've found water to be more effective.” - Adrianne Ambrose
Today, we go across the pond to take a look at Celyad (CYAD). This company is a small CAR-T focused ‘Tier 4’ developmental concern that is targeting multiple indications. A full analysis of this interesting and bit of an 'off the radar' name is provided in the paragraphs below.
Company Overview:
Celyad is a Mont-Saint-Guibert, Belgium-based clinical-stage biopharmaceutical company that is focused on reversing the outcomes of severe diseases. Celyad’s ordinary shares are listed on